Which test to use to measure the anticoagulant effect of rivaroxaban: The prothrombin time test

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 4, 2013, Pages 576-578

  Tripodi, A ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RIVAROXABAN;

ANTICOAGULANT THERAPY; ARTICLE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG RESPONSE; HUMAN; MEASUREMENT; PRIORITY JOURNAL; PROTHROMBIN TIME; STANDARDIZATION;

ANTICOAGULANTS; HUMANS; MORPHOLINES; PROTHROMBIN TIME; THIOPHENES;

EID: 84876190337     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12166     Document Type: Article

References (10)

1. Tripodi A, Palareti G. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. J Intern Med 2012; 271: 554-65.
2. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Manotti C. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-76.
3. Rohde G. Determination of rivaroxaban - a novel, oral, direct factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872: 43-50.
4. Samama MM, Martinoli JL, Le Flem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-25.
5. Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010; 104: 1078-9.
6. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL. Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-87.
7. Tripodi A, Chantarangkul V, Guinet C, Samama MM. The INR calibrated for rivaroxaban-(INRrivaroxaban) has the potential to normalize PT results for rivaroxaban-treated patients. Results of an in-vitro study. J Thromb Haemost 2011; 9: 226-8.
8. Harenberg J, Marx S, Krämer R, Giese C, Weiss C. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis 2011; 22: 637-41.
9. van den Besselaar AMHP, Poller L, Tripodi A. World Health Organization (WHO) Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy. WHO Technical Report Series, No. 889, 1999;64-93.
10. Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C, Gourmelin Y, Martinoli JL; Rivaroxaban Prothrombin Time Field Trial Laboratories. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 2012; 18: 150-8.